Skip to main content

Month: March 2023

NVIDIA, ASML, TSMC and Synopsys Set Foundation for Next-Generation Chip Manufacturing

Semiconductor Leaders Embrace NVIDIA Breakthrough in Computational Lithography as Industry Drives to the Limits of PhysicsNVIDIA cuLitho for Computational Lithography NVIDIA cuLitho brings accelerated computing to computational lithography, enabling the semiconductor industry to accelerate the design and manufacturing of next-generation chips.SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) — GTC — NVIDIA today announced a breakthrough that brings accelerated computing to the field of computational lithography, enabling semiconductor leaders like ASML, TSMC and Synopsys to accelerate the design and manufacturing of next-generation chips, just as current production processes are nearing the limits of what physics makes possible. The new NVIDIA cuLitho software library for computational lithography is being integrated...

Continue reading

Medtronic and NVIDIA Collaborate to Build AI Platform for Medical Devices

Integrating NVIDIA Technology Into Medtronic’s Real-Time AI Endoscopy Device to Help Improve Patient Care and OutcomesMedtronic AI Platform Medtronic’s GI Genius intelligent endoscopy module is the first device to integrate NVIDIA healthcare and edge AI technologies as part of the companies’ collaboration to build an AI platform for medical devices.SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) — GTC—NVIDIA today announced that it is collaborating with Medtronic, the world’s largest healthcare technology provider, to accelerate the development of AI in the healthcare system and bring new AI-based solutions into patient care. The companies will integrate NVIDIA healthcare and edge AI technologies into Medtronic’s GI Genius™ intelligent endoscopy module, developed and manufactured by Cosmo Pharmaceuticals....

Continue reading

Precipio Ships First IV-Cell® Order to Major US Healthcare System

Products Division revenues begin to diversify beyond HemeScreen® NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics cell culturing media, to a major US healthcare system. The healthcare system (unnamed for competitive reasons) has successfully completed the validation of the media and will begin the gradual incorporation into clinical use. About IV-Cell® Media Precipio’s IV-Cell® culturing media is a critical reagent intended to be used by cytogenetics laboratories to simplify, speed up and provide greater accuracy of their hematologic (blood cancer) diagnostic processes. It simplifies the cell culturing process by eliminating the need for special mixtures of multiple components for each...

Continue reading

Paylocity Unveils AI Assist™ – Leading the Industry in Integrating Generative AI into HCM Software

Leveraging OpenAI—the developer of ChatGPT—AI Assist Uses Artificial Intelligence to Enable Faster and More Effective Communications Across the Enterprise SCHAUMBURG, Ill., March 21, 2023 (GLOBE NEWSWIRE) — Paylocity (NASDAQ: PCTY) today announced AI Assist™, a landmark achievement in HR technology with the integration of generative Artificial Intelligence (AI) into its core HCM platform. Built using an integration with OpenAI—the developer of ChatGPT—AI Assist gives HR professionals, leaders, and employees the power to create highly effective communications in less time. AI Assist can quickly draft ready-to-send communications and announcements directly in the Paylocity platform based on a simple prompt from users. AI Assist follows several other innovations Paylocity has built into the industry’s most modern HCM...

Continue reading

Sinch Named Adobe Digital Experience Technology Partner of the Year—Customer Journeys

Sinch-Adobe-Tech-Partner-of-the-Year-thumbnail Sinch Named Adobe Digital Experience Technology Partner of the Year—Customer JourneysLAS VEGAS and STOCKHOLM, Sweden – MARCH 21, 2023 – Sinch, which powers meaningful conversations between businesses and their customers through its Customer Communications Cloud, today announced it has been named 2023 Adobe Digital Experience Technology Partner of the Year—Customer Journeys. Adobe’s Digital Experience partner awards honor companies that have made leading contributions to Adobe’s business and have had a significant impact on customer success. The Adobe Digital Experience Technology Partner of the Year—Customer Journeys was awarded to Sinch in part for its innovative customer experiences focused on reducing friction for customers, faster time to value onboarding process, and global customer...

Continue reading

Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities

Company AnnouncementNo. 16/2023         Copenhagen, 21 March 2023 Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a)Name Niels Frederiksen2. Reason for the notificationa)Position/titleCEO and member of the Executive Managementb)Initial notification/amendmentInitial notification3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameScandinavian Tobacco Group A/Sb) LEI code5299003KG4JS99TRML674. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a)Description of the financial instrument,...

Continue reading

Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®*With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulationSandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competitionBasel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira®* (adalimumab), including rheumatoid...

Continue reading

Crown Electrokinetics to Announce Fourth Quarter and Year End 2022 Results on March 31, 2023

LOS ANGELES, March 21, 2023 (GLOBE NEWSWIRE) — Crown Electrokinetics Corp. (NASDAQ: CRKN) (“Crown” or the “Company”), a leading smart glass technology company and an expert in both designing and installing distributed antenna systems (DAS) and constructing fiber optic networks, today announced that it will report its fourth quarter and year end 2022 financial results on March 31, 2023. The Company will host a conference call and audio webcast that morning at 11:00 a.m. Eastern time featuring remarks by Doug Croxall, Chairman & CEO and Joel Krutz, CFO. Conference Call Information To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call. Date: March 31, 2023Time: 11:00 a.m. ESTToll Free: 1-877-451-6152International: 1-201-389-0879Conference...

Continue reading

Friendable Reducing 2023 Operating Expenses by Approximately $1M Dollars, and Leverages Several Years of Technology Assets for New Opportunities

CAMPBELL, CA, March 21, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Friendable Inc. (OTC: FDBL) (the “Company”), a mobile technology and marketing company, is pleased to announce its operational and public market cost reduction initiatives have dramatically reduced costs for the 2023 calendar year, enabling the Company to re-focus resources on strategic re-branding of its Fan Pass Livestream platform for a targeted market opportunity, support its FeaturedX artists/marketplace, and maintain daily operations.  Robert A. Rositano Jr., CEO, Friendable, Inc. stated, “We have a lot of successes to build upon and when you’ve had time to analyze a Company’s product or service, the data/metrics of market testing, the business model itself, and most importantly the time to reflect on a road previously traveled, the next steps become much...

Continue reading

Denuvo unveils Unbotify technology for bot detection

Denuvo Unbotify delivers the next level of hardware cheat and fraud detection through behavioral biometrics analysis, leaving bots with no place to hide.Denuvo Unbotify Denuvo unveils new technology for bot detection in video gamesDenuvo Unbotify Denuvo unveils new technology for bot detection in video gamesAmsterdam, March 21, 2023 (GLOBE NEWSWIRE) — Irdeto, the world leader in digital platform cybersecurity, today announces it is relaunching to the market a unique technology focused on behavioral biometric analysis for bot detection in video games. Denuvo Unbotify is able to identify bots in real-time with 99.8% accuracy. New ways of cheating in online games – and getting away with it – are being developed on a disturbing scale. Both premium and “free to play” (F2P) games often offer rewards either in exchange for real-world...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.